Product Type: Market Research Report
Published by: Espicom Healthcare Intelligence
Published: February 2005
Product Code: R16-243Description Espicom Business Intelligence, publisher of the respected business newsletter CNS Drug News, has produced this thought-provoking analysis Neurodegenerative Drug Futures.
Neurodegenerative disorders are estimated to affect over 22 million people worldwide. Whilst many palliative treatments have become available during the last 15 years, there is still no cure for many of these progressive and debilitating diseases. Furthermore, the rising number of elderly people will ensure that demand for effective treatments in key diseases associated with age continues to grow.
The report provides a comprehensive review of all current and future technologies and also provides detailed summaries on specific neurodegenerative disorders (Alzheimer’s disease, Parkinson’s disease, Multiple sclerosis, Amyotrophic lateral sclerosis and Huntington’s disease).
Everyone concerned with understanding and exploiting this rapidly growing sector needs to be aware of the prospects for the future and the key technologies that could fundamentally change research and clinical approaches for treating this progressive and debilitating disease. In 150+ information-packed pages the study focuses on the products and science that will affect the competitive environment.
Key questions answered by this report include:
- What impact have new technologies had on the drug-development process in neurodegenerative diseases?
- What advances have been made in stem cell research and who are the major players?
- Does gene therapy offer a realistic alternative to small molecule therapies?
- What are the current therapies available for Alzheimer’s disease, Parkinson’s disease, multiple sclerosis and amyotrophic lateral sclerosis and what are their strengths and weaknesses?
- Which novel neurodegenerative compounds may enter the market in the next 5 years?
Table of Contents THE DISEASE - PART 1
WHAT IS MEANT BY NEURODEGENERATIVE DISORDERS?
What is Alzheimer’s disease?
AD is associated with widespread cholinergic loss
What is Parkinson’s disease?
What is multiple sclerosis?
What is amyotrophic lateral sclerosis?
The different nerve tracts affected in primary lateral sclerosis (PLS) and ALS
PATIENT AND DISEASE STATISTICS
Incidence, prevalence in US, Europe and Japan, % diagnosis & % treatment
Alzheimer’s disease statistics
Parkinson's disease statistics
Multiple sclerosis statistics
Amyotrophic lateral sclerosis statistics
CHARACTERISTICS OF NEURODEGENERATIVE DISEASES - THEIR SIMILARITIES AND DIFFERENCES
Pathogenesis of Alzheimer’s disease
Pathogenesis of Parkinson’s disease
Genes/proteins linked to PD pathogenesis
Pathogenesis of multiple sclerosis
Pathogenesis of amyotrophic lateral sclerosis
BIBLIOGRAPHY - PART 1
THE MARKET - PART 2
GLOBAL NEURODEGENERATIVE MARKET
Global CNS markets US$59 billion
Global Alzheimer’s disease market
AD prescription market (US)
Global Parkinson’s disease market
PD prescription market (US)
Global multiple sclerosis market
MS prescription market (US)
Global amyotrophic lateral sclerosis market
PALLATIVE THERAPIES
CURRENT ALZHEIMER’S DISEASE THERAPIES
Acetylcholinesterase inhibitors and Namenda
AChEI label versus NMDA receptor antagonist
Pros and cons of AChEIs and NMDA receptor antagonist
Brief SWOT analysis of AChEIs and Namenda
Strengths
Weaknesses
Opportunities
Threats
US patent expiration of leading AD agents
Conclusions
CURRENT PARKINSON’S DISEASE THERAPIES
Levodopa and dopamine agonists
L-Dopa and dopamine agonists 24
Brief SWOT analysis of dopamine replacement therapies/agonists
Strengths
Weaknesses
Opportunities
Threats
US patent expiration of leading dopamine agonists
Conclusions
CURRENT MULTIPLE SCLEROSIS THERAPIES
Immunomodulators and immunosuppressants
Comparison of leading MS agents
SWOT analysis of MS agent characteristics
Strengths
Weaknesses
Opportunities
Threats
Patent expirations of MS agents
Conclusions
CURRENT AMYOTROPHIC LATERAL SCLEROSIS THERAPIES
SWOT analysis of Rilutek
Strengths
Weaknesses
Opportunities
Threats
Conclusions
BRIEF SUMMARY OF NEW THERAPIES
NEW THERAPIES FOR ALZHEIMER’S DISEASE
Phenserine
Alzhemed
Flurizan
PBT 1
NS2330
Colostinin
Conclusions
NEW THERAPIES FOR PARKINSON’S DISEASE
Neuroprotective/neurorestorative agents
Dopamine replacement therapies
Dopamine agonists
MAO-B inhibitors
Dopamine/monoamine reuptake inhibitors
Adenosine receptor antagonists
Conclusions
NEW THERAPIES FOR MULTIPLE SCLEROSIS
Campath
Cladribine
Laquinimod
BX-471
ABT-874
Gamunex
Conclusions
NEW THERAPIES FOR AMYOTROPHIC LATERAL SCLEROSIS
Minocycline
Neurodex
Ikomio
AEOL 10150
Conclusions
BIBLIOGRAPHY - PART 2
NEW TECHNOLOGIES - PART 3
NEW TECHNOLOGIES FOR UNDERSTANDING THE PATHOGENESIS OF NEURODEGENERATIVE DISEASES
Array technologies
Application in high-throughput screening
Companies at the forefront of array technology
Application of arrays in PD
Application of arrays in neurological diseases
Models of neurodegenerative disease
Animal models for neurodegenerative diseases
Biomarkers
Genetic and biochemical markers for neurodegenerative diseases
Application of biomarkers in the diagnosis of AD
Application of biomarkers in PD
Application of biomarkers in MS
Application of biomarkers in the diagnosis of ALS
Neuroimaging
Summary of neuroimaging technology currently available 55
Application in elucidating the pathophysiology of neurodegenerative diseases
Application in improving the diagnosis of PD
Application in new diagnostic agents for AD
Application to find new treatments for AD
Application to find new treatments for MS
Application to determine the effective treatment of acute stroke
Application in clinical trials as definitive clinical endpoints
Application for new technology platforms
APPENDIX 1 - COMPETITOR ACTIVITY IN IMAGING - ESPICOM DATABASE
BIBLIOGRAPHY - PART 3
NEW TECHNOLOGIES - PART 4
THE APPLICATION OF NEW TECHNOLOGIES - TARGETS AND TREATMENT
STEM CELLS
Stem cell research in CNS disorders
Types of stem cells
Sources of stem cells
Alternative approaches using stem cells
Clinical applications of stem cells
Parkinson’s disease (PD)
In vivo stem cell studies
Foetal stem cell transplants
Adult stem cell transplants
Alzheimer’s disease (AD)
Multiple sclerosis (MS)
Amyotrophic lateral sclerosis (ALS)
Spinal cord injury (SCI)
Ischaemic brain damage
Stem cell research in clinical development
Clinical development of stem cell research
Stem cell research in clinical development
Bioscience companies involved in stem cell research
Biotechnology/bioscience companies involved in stem cell research
Major hurdles surrounding stem cell research
Technical issues surrounding stem cell research
Ethical issues surrounding stem cell research
United States legal and ethical stance
Rest of World legal and ethical stance
Bioethics/ethical implications
Overall conclusions on stem cell research
Schematic of gene therapy technology
Advantages and disadvantages of viral vectors for the treatment of CNS disorders
ANTISENSE
Institutional and academic collaboration in antisense
Biotechnology and academic researchers involved in antisense research
Type of antisense
First-generation antisense - RNase oligodeoxynucleotides (OGN)
Method of transfer
Second generation antisense - peptide nucleic acids (PNAs)
Conclusions
GENE THERAPY 9Gene therapy research in CNS disorders
RNAi gene silencing technology
Outstanding issues with RNAi
Delivery
Safety
Cost and ease of production
Institutional and academic collaboration in RNAi
Biotechnology and academic researchers involved in RNAi research
Conclusions
OVERALL CONCLUSIONS ON GENE THERAPY RESEARCH
APPENDIX 2 - COMPETITOR ACTIVITY IN STEM CELL RESEARCH - ESPICOM DATABASE
Institutional stem cell research
Academic stem cell research
APPENDIX 3 - COMPETITOR ACTIVITY IN ANTISENSE RESEARCH - ESPICOM DATABASE
Institutional antisense research
Academic antisense research
APPENDIX 4 - COMPETITOR ACTIVITY IN RNAI RESEARCH - ESPICOM DATABASE
Institutional RNAi research
Academic antisense research
BIBLIOGRAPHY - PART 4
NEW TECHNOLOGIES - PART 5
GLOSSARY
USEFUL WEBSITES
UPCOMING MEETINGS 2005
RECENT MEETINGS
RECENT NEUROSCIENCE SYMPOSIA
Society for Neuroscience 34th Annual Meeting, Oct. 23-27, 2004
5th Neurobiology of Aging Conference: Protein Misfolding in Alzheimer’s and Other Age-Related Neurodegenerative Diseases
Neurotoxicity Society Satellite Meeting on 1) Iron and Parkinson’s Disease and 2) Neurotoxicity of Substances of Abuse
Ex Vivo Culture of Neural Stem Cells
Stem Cell Update: Can Evolving Developmental Insights Inform Intelligent Therapeutic Translation and Its Limitations?
Is Beta Amyloid the Cause of AD and Best Therapeutic Opportunity?
|
